Drug profile · INN
isatuximab-irfc
SARCLISA
isatuximab-irfc (SARCLISA) is a lymphocyte differentiation antigen cd38 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — isatuximab-irfc
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
isatuximab-irfc (SARCLISA) is a lymphocyte differentiation antigen cd38 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Lymphocyte differentiation antigen CD38 inhibitor
Primary target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is isatuximab-irfc?
isatuximab-irfc (SARCLISA) is a lymphocyte differentiation antigen cd38 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for isatuximab-irfc?
SARCLISA is a marketed brand name for isatuximab-irfc. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of isatuximab-irfc?
isatuximab-irfc has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.